Ozempic (semaglutide) is FDA approved for three specific uses, all in adults with type 2 diabetes: improving blood sugar control, reducing cardiovascular risk, and protecting kidney function. It is not approved for weight loss, despite its widespread off-label use for that purpose.
The Three FDA-Approved Indications
Ozempic’s FDA label lists three distinct indications, each tied to type 2 diabetes in adults:
- Blood sugar management: As an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Cardiovascular protection: To reduce the risk of major cardiovascular events, specifically cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes and established heart disease.
- Kidney protection: To reduce the risk of sustained kidney function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
All three indications require a diagnosis of type 2 diabetes. Without that diagnosis, any use of Ozempic is considered off-label.
How Ozempic Works in the Body
Semaglutide, the active ingredient in Ozempic, mimics a natural gut hormone called GLP-1 that your body releases after eating. This hormone does several things at once. It signals your pancreas to release more insulin when blood sugar is high, while also dialing back glucagon, a hormone that tells your liver to dump more sugar into the bloodstream. The net effect is tighter blood sugar control without the constant risk of dangerous lows that some older diabetes medications carry, because the insulin release is tied to actual blood sugar levels.
Semaglutide also slows the rate at which food leaves your stomach, which blunts the blood sugar spikes that follow meals. That slower digestion, combined with effects on appetite-regulating signals in the brain, is why many people on Ozempic feel less hungry and lose weight. But that weight loss is a side effect of the medication’s broader actions, not its approved purpose.
Ozempic Is Not Approved for Weight Loss
This is the most common point of confusion. Many people use Ozempic for weight management, but the FDA has never approved it for that purpose. Weight loss with Ozempic is an off-label use prescribed at a doctor’s discretion.
Wegovy is the semaglutide product that is FDA approved for weight management, and it’s approved for adults and children 12 and older. Wegovy also comes in a higher maximum dose than Ozempic. If weight loss is the primary goal rather than blood sugar control, Wegovy is the version that went through the specific clinical trials and regulatory review for that indication. Wegovy has also earned a separate approval to reduce cardiovascular risk in adults with obesity or overweight and established heart disease, an indication that doesn’t require a diabetes diagnosis.
Dosing and How It’s Taken
Ozempic is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. The dosing follows a gradual schedule to minimize side effects, especially nausea. You start at 0.25 mg weekly for four weeks. That starting dose isn’t meant to control blood sugar; it’s purely to let your body adjust. After four weeks, the dose increases to 0.5 mg weekly. If blood sugar still isn’t well controlled after at least another four weeks, the dose can go up to 1 mg weekly.
No dose adjustments are needed for people with kidney problems, including those on dialysis, or for people with liver impairment. Studies showed that neither condition meaningfully changed how the body processes semaglutide.
Who Should Not Take Ozempic
Ozempic carries the FDA’s most serious warning, a boxed warning, about thyroid tumors. In animal studies, semaglutide caused a type of thyroid cancer called medullary thyroid carcinoma. Whether this risk applies to humans isn’t fully established, but as a precaution, Ozempic is off-limits for anyone with a personal or family history of medullary thyroid carcinoma or a rare condition called Multiple Endocrine Neoplasia syndrome type 2.
The FDA label specifically notes that routine monitoring with blood tests or thyroid ultrasounds isn’t recommended for people on Ozempic, because those tests aren’t reliable enough in this context and could lead to unnecessary procedures. However, if you develop a thyroid nodule or have symptoms like a lump in your neck, difficulty swallowing, or persistent hoarseness, that warrants evaluation.
Ozempic is also not approved for children or adolescents. Safety and effectiveness have not been established in anyone under 18.
What “FDA Approved” Actually Means Here
When a drug is FDA approved for a specific condition, it means the manufacturer submitted clinical trial data proving the drug is both safe and effective for that exact use, and the FDA reviewed and accepted that evidence. For Ozempic, that evidence package covers type 2 diabetes management, cardiovascular risk reduction in diabetic patients with heart disease, and kidney protection in diabetic patients with chronic kidney disease. Doctors can legally prescribe Ozempic for other purposes (this is off-label prescribing, which is common across medicine), but the manufacturer cannot market it for those uses, and insurance coverage is often tied to the approved indications.
If you’re taking or considering Ozempic, the approved indication matters because it affects whether your insurance will cover it, what dose you’ll be prescribed, and what monitoring your doctor will recommend. People using it off-label for weight loss, for example, may face higher out-of-pocket costs and may be better served by Wegovy, which was designed and approved for that specific purpose.